New class of antibody cancer drug shows promise
Drug Discovery World
JULY 26, 2023
What’s interesting about IgE is its involvement in our body’s defence against parasites and the particularly powerful immune response it elicits. ” With the safety of MOv18 IgE having been established in cancer patients, biotechnology company Epsilogen has licensed the drug and will continue its clinical development.
Let's personalize your content